Total Holdings
33
As of Oct 4, 2026
Invesco Biotechnology & Genome ETF
PBENYSEARCAInvescoEquity
$96.08Today:- (-)1Y +36.58%
As of Oct 16, 2026 close
- Assets (AUM)
- $424.35M
- Expense ratio
- 0.59%
- Dividend yield
- 1.35%
- Holdings
- 33
- 52-week range
- $70.83$98.82
- Volume (live)
- -
- Avg. volume (3M)
- 12.08K
PBE ETF Holdings: Invesco Biotechnology & Genome ETF
Every listed position with its portfolio weight, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Top 10 Holdings
49.2%
Share of fund assets
Assets (AUM)
$424.35M
Total fund assets
Expense Ratio
0.59%
Annual management fee
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 31 of 33 PBE Holdings by Portfolio Weight
Holdings as of Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position. Fund disclosures available to us list the largest 31 positions.
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Natera, Inc. | Stock | 6.31% |
| 2 |  | Illumina, Inc. | Stock | 6.29% |
| 3 |  | Biogen Inc | Stock | 5.18% |
| 4 |  | Gilead Sciences, Inc | Stock | 5.18% |
| 5 |  | Regeneron Pharmaceuticals, Inc | Stock | 5.01% |
| 6 |  | Royalty Pharma plc | Stock | 5.00% |
| 7 |  | Vertex Pharmaceuticals Incorporated | Stock | 4.94% |
| 8 |  | Amgen Inc. | Stock | 4.72% |
| 9 |  | Moderna, Inc. | Stock | 3.38% |
| 10 |  | Sarepta Therapeutics, Inc | Stock | 3.17% |
| 11 |  | Novavax, Inc. | Stock | 3.13% |
| 12 |  | United Therapeutics Corporation | Stock | 2.95% |
| 13 |  | Neurocrine Biosciences, Inc | Stock | 2.94% |
| 14 |  | Veracyte, Inc. | Stock | 2.94% |
| 15 |  | Exelixis, Inc. | Stock | 2.91% |
| 16 |  | Qiagen N.V. | Stock | 2.90% |
| 17 |  | BioMarin Pharmaceutical Inc | Stock | 2.88% |
| 18 |  | Halozyme Therapeutics, Inc. | Stock | 2.84% |
| 19 |  | Repligen Corporation | Stock | 2.83% |
| 20 |  | Protagonist Therapeutics Inc | Stock | 2.82% |
| 21 |  | TG Therapeutics, Inc | Stock | 2.80% |
| 22 |  | Incyte Corporation | Stock | 2.70% |
| 23 |  | Ardelyx, Inc | Stock | 2.67% |
| 24 |  | AnaptysBio, Inc | Stock | 2.66% |
| 25 |  | Vericel Corporation | Stock | 2.63% |
| 26 |  | PTC Therapeutics, Inc | Stock | 2.60% |
| 27 |  | ACADIA Pharmaceuticals Inc | Stock | 2.58% |
| 28 |  | Legend Biotech Corporation | Stock | 2.50% |
| 29 |  | BioCryst Pharmaceuticals Inc | Stock | 2.40% |
| 30 |  | Collegium Pharmaceutical Inc | Stock | 2.38% |
| 31 | NMFQS:AGPXX | Short-Term Investment Trust - Invesco Government & Agency Portfolio | Cash | 0.10% |
Source: Fund holdings disclosures. Data as of Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About Invesco Biotechnology & Genome ETF Holdings
What are the top holdings in PBE?
As of Oct 4, 2026, Invesco Biotechnology & Genome ETF (PBE) holds 33 securities. The largest are Natera, Inc. (6.31%), Illumina, Inc. (6.29%), Biogen Inc (5.18%). The holdings table lists each position by portfolio weight with its ticker, name and asset type.
How concentrated is PBE's portfolio?
As of Oct 4, 2026, the 10 largest positions make up 49.2% of PBE's assets. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly.
What is PBE's sector allocation?
The Sector Allocation chart shows how PBE distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does PBE invest in?
PBE's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is PBE ETF?
PBE's diversification can be assessed by reviewing its 33 holdings (as of Oct 4, 2026), sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.